195 related articles for article (PubMed ID: 36961654)
1. Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
Moreau P; van de Donk NWCJ; Delforge M; Einsele H; De Stefano V; Perrot A; Besemer B; Pawlyn C; Karlin L; Manier S; Leleu X; Weisel K; Ghilotti F; Diels J; Elsada A; Morano R; Strulev V; Pei L; Kobos R; Smit J; Slavcev M; Mateos MV
Adv Ther; 2023 May; 40(5):2412-2425. PubMed ID: 36961654
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Moreau P; Mateos MV; Gonzalez Garcia ME; Einsele H; De Stefano V; Karlin L; Lindsey-Hill J; Besemer B; Vincent L; Kirkpatrick S; Delforge M; Perrot A; van de Donk NWCJ; Pawlyn C; Manier S; Leleu X; Martinez-Lopez J; Ghilotti F; Diels J; Morano R; Albrecht C; Strulev V; Haddad I; Pei L; Kobos R; Smit J; Slavcev M; Marshall A; Weisel K
Adv Ther; 2024 Feb; 41(2):696-715. PubMed ID: 38110653
[TBL] [Abstract][Full Text] [Related]
3. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
Einsele H; Moreau P; Bahlis N; Bhutani M; Vincent L; Karlin L; Perrot A; Goldschmidt H; van de Donk NWCJ; Ocio EM; Martinez-Lopez J; Rodríguez-Otero P; Dytfeld D; Diels J; Strulev V; Haddad I; Renaud T; Ammann E; Cabrieto J; Perualila N; Gan R; Zhang Y; Parekh T; Albrecht C; Weisel K; Mateos MV
Adv Ther; 2024 Apr; 41(4):1576-1593. PubMed ID: 38402374
[TBL] [Abstract][Full Text] [Related]
4. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma.
Mateos MV; Chari A; Usmani SZ; Goldschmidt H; Weisel K; Qi K; Londhe A; Nair S; Lin X; Pei L; Ammann E; Kobos R; Smit J; Parekh T; Marshall A; Slavcev M; Moreau P
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):385-393. PubMed ID: 36967244
[TBL] [Abstract][Full Text] [Related]
5. Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma.
Krishnan A; Nooka AK; Chari A; Garfall AL; Martin TG; Nair S; Lin X; Qi K; Londhe A; Pei L; Ammann E; Kobos R; Smit J; Parekh T; Marshall A; Slavcev M; Usmani SZ
J Comp Eff Res; 2023 Jun; 12(6):e220186. PubMed ID: 37114426
[No Abstract] [Full Text] [Related]
6. Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.
Miao X; Wu LS; Lin SXW; Xu Y; Chen Y; Iwaki Y; Kobos R; Stephenson T; Kemmerer K; Uhlar CM; Banerjee A; Goldberg JD; Trancucci D; Apte A; Verona R; Pei L; Desai R; Hickey K; Su Y; Ouellet D; Samtani MN; Guo Y; Garfall AL; Krishnan A; Usmani SZ; Zhou H; Girgis S
Target Oncol; 2023 Sep; 18(5):667-684. PubMed ID: 37713090
[TBL] [Abstract][Full Text] [Related]
7. Teclistamab in Relapsed or Refractory Multiple Myeloma.
Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
[TBL] [Abstract][Full Text] [Related]
8. Adjusted comparison of outcomes between patients from CARTITUDE-1
Mateos MV; Weisel K; Martin T; Berdeja JG; Jakubowiak A; Stewart AK; Jagannath S; Lin Y; Diels J; Ghilotti F; Thilakarathne P; Perualila NJ; Cabrieto J; Haefliger B; Erler-Yates N; Hague C; Jackson CC; Schecter JM; Strulev V; Nesheiwat T; Pacaud L; Einsele H; Moreau P
Haematologica; 2023 Aug; 108(8):2192-2204. PubMed ID: 36546453
[TBL] [Abstract][Full Text] [Related]
9. A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Curr Med Res Opin; 2024 Feb; 40(2):199-207. PubMed ID: 38078866
[TBL] [Abstract][Full Text] [Related]
10. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience.
Dima D; Davis JA; Ahmed N; Jia X; Sannareddy A; Shaikh H; Shune L; Kaur G; Khouri J; Afrough A; Strouse C; Lochner J; Mahmoudjafari Z; Raza S; Valent J; Anderson LD; Anwer F; Abdallah AO; Hashmi H
Transplant Cell Ther; 2024 Mar; 30(3):308.e1-308.e13. PubMed ID: 38151105
[TBL] [Abstract][Full Text] [Related]
12. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
[TBL] [Abstract][Full Text] [Related]
13. Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study.
Mateos MV; Weisel K; Diels J; Arribas A; Tamayo M; Schecter JM; Roccia T; Haddad I; Pacaud L; Moreau P
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):224-231.e2. PubMed ID: 38212206
[TBL] [Abstract][Full Text] [Related]
14. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Vogel M; Jackson CC; Deraedt W; Tian H; Yeh TM; Banerjee A; Pacaud L; Garrett A; Haltner A; Cameron C; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2021 Oct; 37(10):1779-1788. PubMed ID: 34256668
[TBL] [Abstract][Full Text] [Related]
15. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
[TBL] [Abstract][Full Text] [Related]
16. A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed/refractory multiple myeloma.
Mol I; Hu Y; LeBlanc TW; Cappelleri JC; Chu H; Nador G; Aydin D; Schepart A; Hlavacek P
Leuk Lymphoma; 2024 May; 65(5):660-668. PubMed ID: 38347747
[TBL] [Abstract][Full Text] [Related]
17. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1.
Cortes-Selva D; Perova T; Skerget S; Vishwamitra D; Stein S; Boominathan R; Lau OS; Nielsen K; Davis C; Patel JH; Banerjee A; Stephenson T; Uhlar C; Kobos R; Goldberg JD; Pei L; Trancucci D; Girgis S; Wang Lin SX; Wu LS; Moreau P; Usmani SZ; Bahlis NJ; van de Donk NWCJ; Verona R
Blood; 2024 Apr; ():. PubMed ID: 38657201
[TBL] [Abstract][Full Text] [Related]
18. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.
Mateos MV; Weisel K; De Stefano V; Goldschmidt H; Delforge M; Mohty M; Cavo M; Vij R; Lindsey-Hill J; Dytfeld D; Angelucci E; Perrot A; Benjamin R; van de Donk NWCJ; Ocio EM; Scheid C; Gay F; Roeloffzen W; Rodriguez-Otero P; Broijl A; Potamianou A; Sakabedoyan C; Semerjian M; Keim S; Strulev V; Schecter JM; Vogel M; Wapenaar R; Nesheiwat T; San-Miguel J; Sonneveld P; Einsele H; Moreau P
Leukemia; 2022 May; 36(5):1371-1376. PubMed ID: 35332278
[TBL] [Abstract][Full Text] [Related]
19. Real-world analysis of teclistamab in 123 RRMM patients from Germany.
Riedhammer C; Bassermann F; Besemer B; Bewarder M; Brunner F; Carpinteiro A; Einsele H; Faltin J; Frenking J; Gezer D; Goldman-Mazur S; Hänel M; Hoegner M; Kortuem KM; Krönke J; Kull M; Leitner T; Mann C; Mecklenbrauck R; Merz M; Morgner A; Nogai A; Raab MS; Teipel R; Wäsch R; Rasche L
Leukemia; 2024 Feb; 38(2):365-371. PubMed ID: 38245601
[TBL] [Abstract][Full Text] [Related]
20. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Martin T; Usmani SZ; Schecter JM; Roccia T; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Pacaud L; Garrett A; Bartlett M; Haltner A; Van Sanden S; Diels J; Valluri S; Samjoo IA
Curr Med Res Opin; 2023 Jan; 39(1):81-89. PubMed ID: 36271807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
